State, local access to federal device contracts would cost $1.35 bil. a year -- HIMA rep.
This article was originally published in The Gray Sheet
Executive SummarySTATE, LOCAL PARTICIPATION IN FEDERAL MEDICAL DEVICE CONTRACTS WOULD ADD $1.35 BIL. in annual costs to the federal government, according to results of a study released by Thomas Gunerman, president and CEO of Intersurgical, at a July 27 hearing before the House Committee on Small Business. Gunerman, who represented the Health Industry Manufacturers Association, cited a study conducted by Muse & Associates at HIMA's request which suggested that federal government cost increases experienced with the Medicaid prescription drug rebate program would be repeated for devices under Sec. 1555 of the Federal Acquisition Streamlining Act of 1994 (FASA).
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.